Table : Cancer Patients waiting >104 days Tumour Group Number of Patients Number of patients Waiting with Waiting Without Decision to Treat Decision to Treat Breast 0 0 Gynae 0 1 Head & Neck 1 1 HPB 0 1 Lower GI 1 2 Lung 0 1 Sarcoma 1 1 Skin 0 1 Upper GI 1 1 Urology 3 2 Total 7 11 The Corporate Cancer Team continues to review and discuss cancer pathways with each Directorate to ensure that cancer remains a high priority. Areas that continue to be a cause for concern are endoscopy, radiology (particularly breast radiology) and elements of the pathology service. Table : Cancer Targets as at September 2016 1 2 Cancer May-16 16/17 16/17 Aug-16 Jul-16 Sep-16 Jun-16 Quarter Quarter All cancers: 2 week wait (C,M) 96.0% 95.8% 95.9% 95.7% 96.5% 94.6% 95.6% (Target 93.0%) 2 Week Wait for Symptomatic Breast Patients (Cancer Not initially 97.0% 96.7% 96.4% 95.2% 96.4% 94.1% 95.1% Suspected) (C,M) (Target 93.0%) All cancers: 1 month diagnosis to first treatment 97.7% 97.9% 97.9% 98.7% 98.2% 98.2% 98.4% (C,M) (Target 96.0%) All cancers: 1 month diagnosis to subsequent 94.1% 96.8% 96.8% 96.8% 97.5% 93.5% 95.8% treatment – surgery (C,M) (Target 94.0%)
Table : Cancer Patients waiting >104 days Tumour Group Number of Patients Waiting with Decision to Treat Number of patients Waiting Without Decision to Treat Breast 0 0 Gynae 0 1 Head & Neck 1 1 HPB 0 1 Lower GI 1 2 Lung 0 1 Sarcoma 1 1 Skin 0 1 Upper GI 1 1 Urology 3 2 Total 7 11 The Corporate Cancer Team continues to review and discuss cancer pathways with each Directorate to ensure that cancer remains a high priority. Areas that continue to be a cause for concern are endoscopy, radiology (particularly breast radiology) and elements of the pathology service. Table : Cancer Targets as at September 2016 Cancer May-16 Jun-16 Quarter 1 16/17 Jul-16 Aug-16 Sep-16 Quarter 2 16/17 All cancers: 2 week wait (C,M) (Target 93.0%) 96.0% 95.8% 95.9% 95.7% 96.5% 94.6% 95.6% 2 Week Wait for Symptomatic Breast Patients (Cancer Not initially Suspected) (C,M) (Target 93.0%) 97.0% 96.7% 96.4% 95.2% 96.4% 94.1% 95.1% All cancers: 1 month diagnosis to first treatment (C,M) (Target 96.0%) 97.7% 97.9% 97.9% 98.7% 98.2% 98.2% 98.4% All cancers: 1 month diagnosis to subsequent treatment – surgery (C,M) (Target 94.0%) 94.1% 96.8% 96.8% 96.8% 97.5% 93.5% 95.8%
A5(ii)_BDP_October_Board_report.docx